Genomics Moves into the Clinic

Genomics moves into the clinic.

Plant genomics moves into the limelight.

Two major considerations impelled Ronald Phillips [University of Minnesota and Director of the National Research Initiative of the U.S. Department of Agriculture (USDA)], and Michael Freeling (University of California, Berkeley), to organize a recent colloquium, ‘‘Protecting our Food Supply: The Value of Plant Genome Initiatives’’ (Stanford, CA, June 2–5). First, the increased wealth of the dev...

New strategies in prostate cancer: translating genomics into the clinic.

With the rapidly developing use of next-generation sequencing technologies, there has been a surge in our knowledge of the genomic landscape of prostate cancer and a movement toward developing a molecular subclassification system for the disease. With this new understanding comes great clinical potential, both for the development of biomarkers as well as new therapeutic targets. Herein, we high...

Laetrile: the battle moves into the courtroom.

Blocking cancer with RNA interference moves toward the clinic.

The discovery of RNA interference (RNAi), the endogenous regulatory system that employs small doublestranded RNA molecules to silence gene expression, has generated enthusiasm for using small interfering RNA – based molecules (siRNA) to treat a variety of diseases. It didn’t take long for investigators to dream up several strategies for siRNA to target cancer. And recent studies offer tantalizi...